Selective lysis of NK-sensitive target cells by a soluble mediator released from murine spleen cells and human peripheral blood lymphocytes.

Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med (1984) 3.06

Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med (1984) 2.33

Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum. Infect Immun (1983) 1.60

Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells. J Exp Med (1986) 1.41

High activity of N-alpha-benzyloxycarbonyl-L-lysine thiobenzyl ester serine esterase and cytolytic perforin in cloned cell lines is not demonstrable in in-vivo-induced cytotoxic effector cells. Proc Natl Acad Sci U S A (1987) 1.09

Mannose 6-, fructose 1-, and fructose 6-phosphates inhibit human natural cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (1981) 1.04

Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest (1983) 0.96

YAC-1 variant clones selected for resistance to natural killer cytotoxic factors are also resistant to natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (1983) 0.82

Effect of simple sugars on natural killing: evidence against the involvement of a lectin like mechanism in target recognition. Clin Exp Immunol (1983) 0.82

Impaired release of natural killer cytotoxic factor in patients with primary Sjögren's syndrome. Clin Exp Immunol (1988) 0.80

Recognition specificities, development and possible biological function of natural killer cells in the mouse. II. Changes in NK recognition during ontogeny and ageing, and examination of role of environment in controlling the expressed recognition repertoire. Immunology (1984) 0.75

Effect of interferons on the inhibition of human natural killers by primary monolayer cell cultures. Immunology (1987) 0.75

Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene (2006) 4.06

Effect of low concentrations of ozone on inhaled allergen responses in asthmatic subjects. Lancet (1991) 3.92

Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun (1995) 2.87

Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science (1998) 2.26

Cytotoxic mechanism of tumor necrosis factor-alpha. FASEB J (1990) 2.17

Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol (1979) 1.80

Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy (2011) 1.73

Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology (2004) 1.66

Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med (1996) 1.63

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res (2001) 1.59

Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res (2001) 1.59

Scottish Confidential Inquiry into Asthma Deaths (SCIAD), 1994-6. Thorax (1999) 1.59

Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol (1988) 1.54

Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.53

Human tear lysozyme. II. Quantitative determination with standard Schirmer strips. Am J Ophthalmol (1968) 1.46

Distal splenorenal vs. portal-systemic shunts after hemorrhage from varices: a randomized controlled trial. Hepatology (1988) 1.45

Evidence for several cell populations active in antibody dependent cellular cytotoxicity. J Immunol (1973) 1.44

Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells. J Immunol (1982) 1.42

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm (1997) 1.40

Antimicrobial activity of rabbit CAP18-derived peptides. Antimicrob Agents Chemother (1993) 1.40

Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol (1992) 1.39

Amyloidosis complicating inflammatory bowel disease. A case report and review of the literature. Dig Dis Sci (1990) 1.39

A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol (1994) 1.39

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. J Immunol (1986) 1.34

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene (2009) 1.34

Cellular immunoadsorbents: a simplified technique for separation of lymphoid cell populations. J Immunol (1974) 1.34

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33

The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype. J Exp Med (1988) 1.30

Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol (1996) 1.30

Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. J Immunol (1979) 1.29

Studies on the induction and expression of T cell-mediated immunity. X. Inhibition by Lyt 2,3 antisera of cytotoxic T lymphocyte-mediated antigen-specific and -nonspecific cytotoxicity: evidence for the blocking of the binding between T lymphocytes and target cells and not the post-binding cytolytic steps. J Immunol (1980) 1.25

Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem (1989) 1.25

Distal splenorenal shunt vs. portal-systemic shunt: current status of a controlled trial. Hepatology (1981) 1.24

Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol (1999) 1.24

Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer (2002) 1.22

Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis. J Immunol (1980) 1.21

MR imaging of phagocytosis in experimental gliomas. Radiology (1995) 1.20

Anti-microbial activity of human CAP18 peptides. Immunotechnology (1995) 1.15

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J Immunol (1987) 1.15

Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res (1995) 1.15

Histamine-receptor leucocytes (HRL). Organ and lymphoid subpopulation distribution in man. Clin Exp Immunol (1977) 1.13

Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology (1991) 1.13

Concanavalin A-mediated activation of antigen-primed lymphocytes into secondary cytotoxic lymphocytes. J Exp Med (1977) 1.13

Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents (2003) 1.13

Studies on the mechanism of natural killer cytotoxicity. II. coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells. J Immunol (1983) 1.13

Histamine receptor-bearing leukocytes (HRL). I. Detection of histamine receptor-bearing cells by rosette formation with histamine-coated erythrocytes. J Immunol (1974) 1.13

Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients. J Immunol (1990) 1.13

Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect Immun (1994) 1.12

Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol (1997) 1.11

Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol (1995) 1.11

Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells. J Clin Immunol (1988) 1.07

Lectin-dependent cellular cytotoxicity in man. Transplantation (1977) 1.06

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene (2007) 1.04

Smoking and neurogenerative diseases. Lancet (1993) 1.04

Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol (1995) 1.04

Antibody dependent cellular cytotoxicity: cytotoxicity mediated by non t-lymphocytes. Clin Immunol Immunopathol (1974) 1.03

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol (2001) 1.03

Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol (1991) 1.03

Specific antibodies to dinucleotides and trinucleotides. Eur J Biochem (1972) 1.02

Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay. J Immunol (1982) 1.02

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene (2006) 1.02

Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun (1999) 1.02

Death from airways obstruction: accuracy of certification in Northern Ireland. Thorax (1996) 1.01

The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother (1997) 1.01

Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. Exp Neurol (1997) 1.01

Proteins in human tears. I. Immunoelectrophoretic patterns. Arch Ophthalmol (1969) 0.99

Specific enhancement of tumor growth and depression of cell-mediated immunity following sensitization to soluble tumor antigens. Cancer Res (1976) 0.99

Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF). J Immunol (1987) 0.98

2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clin Immunol (2008) 0.98

Prolonged asymptomatic states in HIV-seropositive persons with 50 CD4+ T-cells/mm3: preliminary psychoimmunologic findings. J Acquir Immune Defic Syndr (1993) 0.97

Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer (1999) 0.97

S-phase-specific expression of the Mad3 gene in proliferating and differentiating cells. Biochem J (2001) 0.96

Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer (1994) 0.96

Mechanism of cell-mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte. J Immunol (1984) 0.96

Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia (2008) 0.96

Human tear lysozyme. 3. Preliminary study on lysozyme levels in subjects with smog eye irritation. Am J Ophthalmol (1968) 0.96

Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res (1993) 0.95

Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J Immunol (1999) 0.95

Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell Immunol (1982) 0.95

Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets. Proc Natl Acad Sci U S A (1990) 0.94

Partial purification of estradiol receptor from Xenopus laevis liver and levels of receptor in relation to estradiol concentration. EMBO J (1983) 0.94

Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. Int J Oncol (1998) 0.94

Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res (1995) 0.93

CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol (2000) 0.93

The SJL/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumor interactions, and regulation of tumor growth. Adv Cancer Res (1983) 0.93

Immunological unresponsiveness induced in adult mice to synthetic polypeptides built on multichain polyproline and multichain polyalanine. Immunochemistry (1974) 0.92

Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res (1997) 0.92

Frequency determination of killer cells by a single-cell cytotoxic assay. Methods Enzymol (1983) 0.92

Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. J Clin Immunol (1996) 0.92

Autoimmunity and aging: the age-related response of mice of a long-lived strain to trinitrophenylated syngeneic mouse red blood cells. J Immunol (1976) 0.92

Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res (1999) 0.92

Studies on the induction and expression of T cell-mediated immunity. I. Blocking of cell-mediated cytolysis by membrane antigens. J Immunol (1974) 0.91

Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF). J Immunol (1983) 0.91

Direct estimation of frequency of cytotoxic T lymphocytes by a modified plaque assay. Nature (1976) 0.91

Endotoxin-binding synthetic peptides with endotoxin-neutralizing, antibacterial and anticoagulant activities. Prog Clin Biol Res (1994) 0.90

Studies on the induction and expression of T cell-mediated immunity. VIII. Effector-target junctions and target cell membrane disruption during cytolysis. Cell Immunol (1979) 0.90